PhaseRx EBITDA 2016-2017 | PZRXQ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PhaseRx ebitda from 2016 to 2017. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PhaseRx ebitda from 2016 to 2017. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.9B
Amgen (AMGN)	$155B
Gilead Sciences (GILD)	$141.4B
Vertex Pharmaceuticals (VRTX)	$99.8B
Bristol Myers Squibb (BMY)	$96.9B
GSK (GSK)	$81.3B
CSL (CSLLY)	$67.8B
Regeneron Pharmaceuticals (REGN)	$62.2B
Alnylam Pharmaceuticals (ALNY)	$59.5B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$28.4B
BioNTech SE (BNTX)	$24.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.9B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.7B
Exelixis (EXEL)	$10.4B
Moderna (MRNA)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.8B
Halozyme Therapeutics (HALO)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B